TY - JOUR AU - Pondel, Kamil AU - Kawałko, Kinga AU - Bielewicz, Krzysztof AU - Chmura, Anna AU - Karaś, Anna PY - 2022/08/30 Y2 - 2024/03/29 TI - Effect of glucagon-like peptide-1 (GLP-1) agonists on the example of semaglutide on the cardiovascular system and their role in the treatment of obesity. JF - Journal of Education, Health and Sport JA - J Educ Health Sport VL - 12 IS - 9 SE - Review Articles DO - 10.12775/JEHS.2022.12.09.007 UR - https://apcz.umk.pl/JEHS/article/view/39508 SP - 55-60 AB - <p>Obesity nowadays affects an increasing number of people. We can talk about it when the patient's BMI is ≥ 30.0 kg/m² (BMI 25.0-29.9 kg/m² - overweight). While obesity in itself may not be a problem for people suffering from it, its complications can be global and sometimes pose a serious threat to health or even life. Its main complications in the cardiovascular system include: hypercholesterolaemia, arterial hypertension, left ventricular hypertrophy, early atherosclerotic changes, heart and cerebral infarction. Treatment of obesity is based mainly on changing the patient's lifestyle - diet and physical activity, which can sometimes be problematic and difficult to apply.</p><p>However, there is a new group of hypoglycaemic drugs - glucagon-like peptide-1 (GLP-1) agonists, which can make obesity treatment easier. These drugs use the incretin effect in the body to increase insulin secretion in response to a meal containing carbohydrates and prevent postprandial hyperglycemia. In this article, we will analyze the latest studies on the effects of GLP-1 receptor agonists, using semaglutide as an example, on the cardiovascular system and on weight loss in patients.</p> ER -